Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Ono Looks for New Growth through Opdivo Despite NHI Price Cut: President
February 16, 2017
- Bristol-Myers Looks to Crack into Genotype 1 Hep C Market as Ximency Clears Resistance Mutation Hurdle
February 15, 2017
- Keytruda Now Available in Japan
February 15, 2017
- AbbVie’s 8-Week Hep C Therapy Filed in Japan
February 15, 2017
- Otsuka Aims for Abilify Maintena’s 30% Share in LAI Antipsychotic Market
February 15, 2017
- Otsuka’s 2016 Earnings Falter as Abilify Sales Dive 70%
February 15, 2017
- Bisphosphonates Grab Top Share, PTH Preparations Expand in FY2015 Osteoporosis Market: Report
February 14, 2017
- Test Urine Copper in Pregnant Women Taking Nobelzin: Nobelpharma
February 14, 2017
- Maruho to Hand Over Joint Disorder Med to Ayumi
February 14, 2017
- Otsuka Aims to Resubmit NDA for Sensor-Embedded Abilify in US by Mid-Year
February 14, 2017
- Sawai Gets FDA Nod for Livalo Generic
February 13, 2017
- Daiichi Sankyo Shutters Research Unit Asubio amid R&D Rejig
February 13, 2017
- Novartis Seeks Pediatric CML Indication for Tasigna
February 13, 2017
- Bayer Yakuhin Ramping Up Digital Transformation: New President
February 10, 2017
- Harvoni No. 1 Drug in Japan in 2016 with Sales of 296 Billion Yen, More than Any Other Drug Over Past 10 Years: IMS Japan
February 10, 2017
- Sandoz Looks to Double Japan Sales by 2022
February 9, 2017
- Ethical Drug Sales Down 8.2% in December: Crecon
February 8, 2017
- OrphanPacific to Distribute Diazoxide from April
February 7, 2017
- Akihisa Nabeshima to Become Teijin Pharma President
February 7, 2017
- FDA Snubs Daiichi Sankyo’s Nausea Med
February 7, 2017
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…